Generic Name: filgotinib
Brand Name: TBC
Manufacturer: Gilead Sciences Canada, Inc.
Indications: Arthritis, Rheumatoid
Manufacturer Requested Reimbursement Criteria1: Indicated as monotherapy, or in combination with methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), for reducing signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.
Submission Type: New
Project Status: Pending
Call For Patient Input: July 6, 2020
Patient Input Closed: August 25, 2020
Anticipated Date: August 4, 2020
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.